Research Domain - Smoking Cessation, Harm Reduction and Biomarkers
Alcohol, Tobacco and Other Substances Anthropometrics Bone and Joint Cancer Cancer Outcomes and Survivorship Cardiovascular Demographics Diabetes Environmental Exposures Gastrointestinal Genomic Medicine Implementation Geriatrics Infectious Diseases and Immunity Neurology Nutrition and Dietary Supplements Obesity Ocular Oral Health Pediatric Development Physical Activity and Physical Fitness Pregnancy Psychiatric Psychosocial Rare Genetic Conditions Reproductive Health Respiratory Skin Smoking Cessation, Harm Reduction and Biomarkers
Social Environments Speech, Language and Hearing
| Select | Protocol | ID |
|---|---|---|
|
#331001 |
|
|
#330101 |
|
|
#330201 |
|
|
#330301 |
|
|
#330401 |
|
|
#330501 |
|
|
#330503 |
|
|
#330502 |
|
|
#330504 |
|
|
#330505 |
|
|
#330601 |
|
|
#330701 |
|
|
#330801 |
|
|
#330901 |
Amount, Type, and Frequency of Recent Use of Nicotine Products |
|
Ethnicity and Race |
|
Expired Carbon Monoxide |
|
Gender Identity |
|
Heaviness of Smoking Index |
|
Motivation to Quit - Multiple Item |
|
Motivation to Quit - Single Item |
|
Point-Prevalence Abstinence from Tobacco Products |
|
Prolonged Abstinence from Tobacco Products |
|
Self-Efficacy for Not Smoking |
|
Sex Assigned at Birth |
|
Smoking Quit Attempts |
Cigarette Smoking Status - Adolescent |
|
Cigarette Smoking Status - Adult |
|
Nicotine Content |
|
Passive Smoke Exposure |
|
Personal Perception and Knowledge of Smoking-related Cancer Risk |
|
Tobacco (non-cigarette) - Product Use |
|
Tobacco - 30-Day Quantity and Frequency - Adolescent |
|
Tobacco - 30-Day Quantity and Frequency - Adult |
|
Tobacco - Age of Initiation of Use - Adolescent |
|
Tobacco - Age of Offset of Cigarette Use - Adolescent |
|
Tobacco - Age of Offset of Cigarette Use - Adult |
Adipocytokines |
|
Anxiety Disorders Screener - Adult |
|
Birth Weight - Measured Weight at Birth |
|
Blood Pressure (Adult/Primary) |
|
Cancer: Personal and Family History |
|
Depression Screener - Adults |
|
Fasting Serum Insulin |
|
Gestational Age - Maternal Interview |
|
History of Stroke - Ischemic Infarction and Hemorrhage |
|
Myocardial Infarction |
|
Peak Expiratory Flow Rate (PEFR) |
|
Periodontal Disease - Prevalence |
|
Personal and Family History of Respiratory Symptoms/Diseases - Adult |
|
Personal and Family History of Respiratory Symptoms/Diseases - Child |
|
Personal History of Allergies, Infectious Diseases, and Immunizations - Adult |
|
Personal History of Type I and Type II Diabetes |
|
Personal Medical History of Allergies, Infectious Diseases, and Immunizations - Child |
|
Pulmonary Embolism |
|
Quality of Life - Adult |
|
Respiratory Rate - Adult |
|
Respiratory Rate - Child |
|
Spirometry - Adult |
|
Spirometry - Child |
Release Date:
February 23, 2021
Scope of Domain:
| Scope Elements | Final Protocols To Toolkit (14) |
|---|---|
| Biomarkers | Nicotine Metabolite Ratio - Serum and Saliva |
| Mechanism of Cessation/Outcomes | Cessation Milestones: Abstinence from Cigarettes |
| Mechanism of Cessation/Outcomes | Point-Prevalence Abstinence from Tobacco Products |
| Mechanism of Cessation/Outcomes | Prolonged Abstinence from Tobacco Products |
| Mediators of Treatment Effects | Perception of Tobacco Product Harm - Cigarettes* |
| Mediators of Treatment Effects | Perception of Tobacco Product Harm - Cigars* |
| Mediators of Treatment Effects | Perception of Tobacco Product Harm - E-Cigarettes* |
| Mediators of Treatment Effects | Perception of Tobacco Product Harm - Pipe Tobacco* |
| Mediators of Treatment Effects | Perception of Tobacco Product Harm - Smokeless Tobacco* |
| Risk Factors | Heaviness of Smoking - Cigarettes |
| Risk Factors | Self-Efficacy for Not Smoking |
| Risk Factors | Social Support for Quitting Smoking |
| Treatment | Adherence to Smoking Cessation Medication - Self-Report |
| Treatment | Methods of Quitting Smoking Cigarettes - Adults |
| *Perception of Tobacco Product Harm assesses both Mediators of Treatment Effects and Risk Factors. |
Working Group Roster:
WG Members:
|
Laura J. Bierut, MD, Co-Chair Washington University in St. Louis St. Louis, MO |
Gary E. Swan, PhD, Co-Chair Stanford University School of Medicine Stanford, CA |
|
Neal L. Benowitz, MD University of California, San Francisco San Francisco, CA |
K. Michael Cummings, PhD, MPH Medical University of South Carolina Charleston, SC |
|
Robin J. Mermelstein, PhD University of Illinois at Chicago Institute for Health Research and Policy Chicago, IL |
Megan E. Piper, PhD University of Wisconsin, Madison Madison, WI |
|
Scott I. Vrieze, PhD University of Minnesota Minneapolis, MN |
Theodore Wagener, PhD The Ohio State University Columbus, OH |
SC Liaison, WG Manager and WG Supervisor:
|
Tabitha P. Hendershot, BA, SC Liaison RTI International Washington, DC |
Cataia Ives, MS, WG Manager RTI International Research Triangle Park, NC |
|
Mark Nelms, PhD, WG Supervisor RTI International Research Triangle Park, NC |
Smoking Cessation, Harm Reduction and Biomarkers Supplemental Information includes:
Additional Information for Smoking Cessation, Harm Reduction and Biomarkers Measures:
There is no additional information for this domain.